These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38096402)

  • 21. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
    Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
    J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
    Ferrante M; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; D'Haens G
    Lancet; 2022 May; 399(10340):2031-2046. PubMed ID: 35644155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
    BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vedolizumab for induction and maintenance of remission in Crohn's disease.
    Hui S; Sinopoulou V; Gordon M; Aali G; Krishna A; Ding NS; Boyapati RK
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD013611. PubMed ID: 37458279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study.
    Cohen NA; Plevris N; Kopylov U; Grinman A; Ungar B; Yanai H; Leibovitzh H; Isakov NF; Hirsch A; Ritter E; Ron Y; Shitrit AB; Goldin E; Dotan I; Horin SB; Lees CW; Maharshak N
    United European Gastroenterol J; 2020 Nov; 8(9):1076-1085. PubMed ID: 32807038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program.
    Sandborn WJ; Vermeire S; Tyrrell H; Hassanali A; Lacey S; Tole S; Tatro AR;
    Adv Ther; 2020 Jul; 37(7):3417-3431. PubMed ID: 32445184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study).
    Hibi T; Imai Y; Senoo A; Ohta K; Ukyo Y
    J Gastroenterol; 2017 Oct; 52(10):1101-1111. PubMed ID: 28324167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study.
    Vermeire S; Ghosh S; Panes J; Dahlerup JF; Luegering A; Sirotiakova J; Strauch U; Burgess G; Spanton J; Martin SW; Niezychowski W
    Gut; 2011 Aug; 60(8):1068-75. PubMed ID: 21317177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis.
    Suzuki Y; Motoya S; Hanai H; Matsumoto T; Hibi T; Robinson AM; Mostafa NM; Chao J; Arora V; Camez A; Thakkar RB; Watanabe M
    J Gastroenterol; 2014 Feb; 49(2):283-94. PubMed ID: 24363029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Etrolizumab for induction of remission in ulcerative colitis.
    Rosenfeld G; Parker CE; MacDonald JK; Bressler B
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011661. PubMed ID: 26630451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.
    Vermeire S; Danese S; Zhou W; Ilo D; Klaff J; Levy G; Yao X; Chen S; Sanchez Gonzalez Y; Hébuterne X; Lindsay JO; Higgins PDR; Cao Q; Nakase H; Colombel JF; Loftus EV; Panaccione R
    Lancet Gastroenterol Hepatol; 2023 Nov; 8(11):976-989. PubMed ID: 37683686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.
    Rubin DT; Cohen RD; Sandborn WJ; Lichtenstein GR; Axler J; Riddell RH; Zhu C; Barrett AC; Bortey E; Forbes WP
    J Crohns Colitis; 2017 Jul; 11(7):785-791. PubMed ID: 28333362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
    Rutgeerts P; Van Assche G; Sandborn WJ; Wolf DC; Geboes K; Colombel JF; Reinisch W; ; Kumar A; Lazar A; Camez A; Lomax KG; Pollack PF; D'Haens G
    Gastroenterology; 2012 May; 142(5):1102-1111.e2. PubMed ID: 22326435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II).
    Danese S; Vermeire S; Hellstern P; Panaccione R; Rogler G; Fraser G; Kohn A; Desreumaux P; Leong RW; Comer GM; Cataldi F; Banerjee A; Maguire MK; Li C; Rath N; Beebe J; Schreiber S
    Gut; 2019 Jan; 68(1):40-48. PubMed ID: 29247068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.
    Sandborn WJ; Lee SD; Tarabar D; Louis E; Klopocka M; Klaus J; Reinisch W; Hébuterne X; Park DI; Schreiber S; Nayak S; Ahmad A; Banerjee A; Brown LS; Cataldi F; Gorelick KJ; Cheng JB; Hassan-Zahraee M; Clare R; D'Haens GR
    Gut; 2018 Oct; 67(10):1824-1835. PubMed ID: 28982740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease.
    Watanabe M; Hibi T; Lomax KG; Paulson SK; Chao J; Alam MS; Camez A;
    J Crohns Colitis; 2012 Mar; 6(2):160-73. PubMed ID: 22325170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.
    Sandborn WJ; Bhandari BR; Randall C; Younes ZH; Romanczyk T; Xin Y; Wendt E; Chai H; McKevitt M; Zhao S; Sundy JS; Keshav S; Danese S
    J Crohns Colitis; 2018 Aug; 12(9):1021-1029. PubMed ID: 29767728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study.
    Sandborn WJ; Rutgeerts P; Colombel JF; Ghosh S; Petryka R; Sands BE; Mitra P; Luo A
    J Crohns Colitis; 2017 Jul; 11(7):811-819. PubMed ID: 28333187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.